Details for Patent: 9,289,432

Which drugs does patent 9,289,432 protect, and when does it expire?

Patent 9,289,432 protects NAYZILAM and is included in one NDA.

Summary for Patent: 9,289,432

Title:	Methods and compositions for the delivery of a therapeutic agent
Abstract:	The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.
Inventor(s):	Gizurarson; Sveinbjorn (Reykjavik, IS)
Assignee:	HANANJA EHF and UNIVERSITY OF ICELAND (Reykjavik, IS)
Application Number:	14/330,654
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,289,432
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 9,289,432

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ucb Inc	NAYZILAM	midazolam	SPRAY;NASAL	211321-001	May 17, 2019		RX	Yes	Yes			Y			ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER

Foreign Priority and PCT Information for Patent: 9,289,432

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Iceland	85932007	Jan 19, 2007